ArticleJournal of health, population, and nutrition2025
Association between non-HDL-C/HDL-C ratio and sarcopenia in US adults: a population-based study.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe non-HDL-C/HDL-C ratio (NHHR) serves as a lipid biomarker indicating the balance of pro-atherogenic and anti-atherogenic lipoproteins in the bloodstream. However, research exploring the effects of NHHR on sarcopenia remains limited. Consequently, this investigation aims to examine the potential correlation between NHHR and sarcopenia.
methodsThis nationwide study used data from the National Health and Nutrition Examination Survey (NHANES) collected between 2011 and 2018. We looked into the correlation of serum NHHR levels with the risk of sarcopenia through multivariable logistic regression. Furthermore, subgroup and sensitivity analyses were carried out to assess the robustness of the findings, and restricted cubic splines were utilized to investigate potential nonlinearities.
resultsThe study encompassed 5,491 participants, of whom 367 (6.68%) were diagnosed with sarcopenia. Elevated NHHR was found to have a significant positive correlation with the incidence of sarcopenia in the fully adjusted model (OR = 1.13, 95% CI: 1.06-1.21, P < 0.001). The occurrence of sarcopenia was 2.11 times higher in participants in the highest NHHR quartile than in the lowest quartile (95% CI: 1.13-3.92, P = 0.023). RCS analysis further demonstrated a nonlinear association of NHHR with sarcopenia (P for nonlinear < 0.001). Extensive subgroup and sensitivity analysis produced consistent outcomes, supported the validity of our findings.
conclusionStudies indicate that NHHR is linked to an elevated risk of sarcopenia among Americans. In an aging society, NHHR might be a useful biomarker for managing and forecasting sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.